|
[1]丛文铭, 吴孟超.肝内胆管癌的微卫星不稳定性和杂合性缺失特点[J].中华肿瘤杂志, 2002, 24 (2) :141.
|
|
[2]丛文铭, 吴孟超.肝癌基因组不稳定性的研究现状与展望[J].第二军医大学学报, 2002, 23 (1) :5-9.
|
|
[3]周福平, 胡和平, 艾建华, 等.运用激光捕获显微切割对肝细胞癌与肝内胆管癌蛋白质组的分析[J].第二军医大学学报, 2005, 26 (10) :1111-1115.
|
|
[4]Kobayashi M, Ikeda K, Saitoh S, et al.Incidence of primarycholangiocellular carcinoma of the liver in japanese patients withhepatitis C virus-related cirrhosis[J].Cancer, 2000, 88 (11) :2471-2477.
|
|
[5]俞文隆, 张永杰, 董辉, 等.肝门部胆管癌的病理生物学特点及其临床意义的研究[J].中华外科杂志, 2009, 47 (15) :1162-1166.
|
|
[6]Varnholt H, Vauthey JN, Dal Cin P.Biliary adenofibroma:arare neoplasm of bile duct origin with an indolent behavior[J].Am J Surg Pathol, 2003, 27 (5) :693-698.
|
|
[7]Borbath I, Verbrugghe L, Lai R, et al.Human equilibrative nu-cleoside transporter 1 (hENT1) expression is a potential predic-tive tool for response to gemcitabine in patients with advancedcholangiocarcinoma[J].Eur J Cancer, 2012, 48 (7) :990-996.
|
|
[8]Mitsuo S, Sugimoto J, Iwahashi S, et al.CD133 expressionis a potential prognostic indicator in intrahepatic cholangiocar-cinoma[J].J Gastroenterol, 2010, 45 (8) :896-902.
|
|
[9]Higashi M, Yamada N, Yokoyama S, et al.Pathobiologicalimplications of MUC16/CA125 expression in intrahepaticcholangiocarcinoma-mass forming type[J].Pathobiology, 2012, 79 (2) :101-106.
|
|
[10]Min JK, Kim JM, Li SJ.L1 cell adhesion molecule is a noveltherapeutic target in intrahepatic cholangiocarcinoma[J].Clin Cancer Res, 2010, 16 (14) :3571-3580.
|
|
[11]Nakanuma Y, Sripa B, Vatanasapt V.Intrahepatic cholangiocar-cinoma.In:Hamilton SR, Aaltonen LA, eds.WHO classifica-tion of tumors, pathology and genetics of tumours of the diges-tive system[M].Lyon:IARC Press, 2000:173-180.
|
|
[12]Komuta M, Spee B, Vander Borght S, et al.Clinicopathologicalstudy on cholangiolocellular carcinoma suggesting hepatic pro-genitor cell origin[J].Hepatology, 2008, 47 (5) :1544-1556.
|
|
[13]Theise ND, Nakashima O, Park YN, et al.In:Bosman FT, Carneiro F, Hruban RH, Theise ND, editors.World healthorganization classification of tumors.WHO classification oftumors of the digestive system[M].Lyon:International A-gency for Research on Cancer, 2010:225-227.
|
|
[14]Kanamoto M, Yoshizumi T, Ikegami T.Cholangiolocellular car-cinoma containing hepatocellular carcinoma and cholangiocel-lular carcinoma, extremely rare tumor of the liver:a case re-port[J].J Med Invest, 2008, 55 (1-2) :161-165.
|
|
[15]Lu XY, Xi T, Lau WY, et al.Hepatocellular carcinoma ex-pressing cholangiocyte phenotype is a novel subtype withhighly aggressive behavior[J].Ann Surg Oncol, 2011, 18 (8) :2210-2217.
|
|
[16]Zhang F, Chen XP, Zhang W, et al.Combined hepatocellularcholangiocarcinoma originating from hepatic progenitor cells:im-munohistochemical and double-fluorescence immunostainingevidence[J].Histopathology, 2008, 52 (2) :224-232.
|
|
[17]Zen C, Zen Y, Mitry RR, et al.Mixed phenotype hepatocellularcarcinoma after transarterial chemoembolization and liver trans-plantation[J].Liver Transplantation, 2011, 17 (8) :943-954.
|
|
[18]Jarnagin WR, Weber S, Tickoo SK.Combined hepatocellularand cholangiocareinoma:demographic, clinical, and prog-nostic factors[J].Cancer, 2002, 94 (7) :2040-2046.
|
|
[19] Ariizumi SI, Kotera Y, Katagiri S, et al.Combined hepatocel-lular-cholangiocarcinoma had poor outcomes after hepatec-tomy regardless of Allen and Lisa class or the predominanceof intrahepatic vholangiocarcinoma cells within the Tumor[J].Ann Surg Oncol, 2012, 19 (5) :1628-1636.
|
|
[20]Kim JH, Yoon HK, Ko GY, et al.Nonresectable combined hepato-cellular carcinoma and cholangiocarcinoma:analysis of the re-sponse and prognostic factors after transcatheter arterial chemo-embolization[J].Radiology, 2010, 255 (1) :270-278.
|
DownLoad: